Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.51 |
| ▸ | MAOA | P21397 | 12/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987089 | 1.00 | MAOB (0.51) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL1986900 | 1.00 | MAOB (0.51) | MAOBMAOAACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL1988599 | 0.98 | MAOB (0.50) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL1988665 | 0.93 | MAOB (0.59) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL2404815 | 0.76 | SLC6A2 (0.44) | ADRA2BADRA2CADRA1AP2RX7 | |
| SCHEMBL11869810 | 0.76 | KDM1A (0.42) | MAOAACHEBCHEP2RX7 | |
| SCHEMBL16795631 | 0.75 | ACHE (0.51) | MAOBMAOAACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL1992094 | 0.75 | P2RX7 (0.34) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL11864699 | 0.74 | GRIN2B (0.47) | ADRA1A | |
| SCHEMBL2345537 | 0.73 | P2RX7 (0.39) | MAOBACHEP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2939669-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-11-04 | — | — | EP | disclosed |
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-02-12 | — | — | US | disclosed |
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-02-12 | — | — | US | disclosed |
| WO-2011087791-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-07-21 | — | — | WO | disclosed |
| US-20110152381-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| US-20110152381-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | PKD1, NAT1, AAAS | MAOB 4099/4885MAOA 2982/4885ACHE 1597/4885 |
| US-20110152381-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | PKD1, NAT1, AAAS | MAOB 4099/4885MAOA 2982/4885ACHE 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.